Skip to content
Gigantum.net
Business

SELLAS Life Sciences stock soars 240% on positive cancer trial

Investing.com -- SELLAS Life Sciences Group (NASDAQ:SLS) shares surged 240% after the company announced positive topline results from its pivotal Phase 3 REG...

· 257 words

Investing.com -- SELLAS Life Sciences Group (NASDAQ:SLS) shares surged 240% after the company announced positive topline results from its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia.

The REGAL trial met its primary endpoint of overall survival, with GPS demonstrating a 41% reduction in the risk of death compared to best available treatment. The trial showed a median overall survival of 24.0 months for GPS-treated patients versus 14.7 months for the control group, with a hazard ratio of 0.59 and a two-sided p-value of 0.035.

The trial evaluated GPS as maintenance monotherapy in patients with acute myeloid leukemia who achieved a second or later complete remission following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.

GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate, most commonly consisting of local injection site reactions.

The topline primary endpoint data analysis was conducted following the pre-specified occurrence of 80 events in accordance with the trial's pre-specified statistical analysis plan. SELLAS plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and advance preparations for a Biologics License Application submission for GPS in the first half of 2027.

Comprehensive statistical evaluation of all secondary endpoints and additional pre-specified analyses is underway and will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal.

Gathered from external sources. Rights to this text belong to whoever originally published it.

Tuesday, November 17, 2026

© 2026 Gigantum.net. Content gathered automatically from external sources; rights to each text belong to whoever originally published it.